文献速递帕金森病与运动障碍认知障碍与痴呆

血液NfL:帕金森病疾病严重程度与进展的生物标志物

Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
PubMed 文献 · Neurology · 2019-08-16

这项前瞻性随访研究纳入178名参与者(116例帕金森病、22例多系统萎缩、40例健康对照),检测血浆神经丝轻链(NfL)水平。帕金森病患者在基线及平均3年随访时评估运动和认知功能。结果显示血浆NfL水平与帕金森病严重程度及运动和认知进展相关,并能区分帕金森病与多系统萎缩。

要点

  • 血浆NfL水平在多系统萎缩组显著高于帕金森病组和健康对照组。
  • 帕金森病患者中,NfL水平在Hoehn-Yahr晚期和痴呆患者中显著升高。
  • 基线NfL较高与运动和认知进展风险增加相关。

核心结论

  • 血浆NfL水平与帕金森病的疾病严重程度以及运动和认知功能进展相关。

研究设计与样本

  • 前瞻性随访研究纳入178名参与者,包括116例帕金森病、22例多系统萎缩和40例健康对照。
  • 采用电化学发光免疫分析法测量血浆NfL水平。
  • 帕金森病患者在基线及平均随访3年时评估运动和认知功能。

主要发现

  • 血浆NfL水平在多系统萎缩组为35.8 ± 6.2 pg/mL,显著高于帕金森病组的17.6 ± 2.8 pg/mL和健康对照组的10.6 ± 2.3 pg/mL(p < 0.001)。
  • 帕金森病组中,Hoehn-Yahr晚期和痴呆患者的NfL水平显著升高(p < 0.001)。
  • NfL水平与UPDRS第三部分评分呈中度相关(r = 0.42,95% CI 0.46-0.56,p < 0.001)。
  • 平均随访3.4 ± 1.2年后,经年龄、性别、病程和基线运动或认知状态调整的Cox回归显示,较高基线NfL水平与运动和认知进展风险增加相关(p = 0.029和p = 0.015)。

关键数值与推荐

  • 血浆NfL水平可区分帕金森病与多系统萎缩(Class III证据)。
  • 基线NfL水平较高与帕金森病运动和认知进展风险增加相关。

临床怎么用

  • 血浆NfL可作为帕金森病疾病严重程度和进展的替代生物标志物。
  • NfL水平有助于区分帕金森病与多系统萎缩。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson disease (PD). METHODS: This prospective follow-up study enrolled 178 participants, including 116 with PD, 22 with multiple system atrophy (MSA), and 40 healthy controls. We measured plasma NfL levels with electrochemiluminescence immunoassay. Patients with PD received evaluations of motor and cognition at baseline and at a mean follow-up interval of 3 years. Changes in the Unified Parkinson's Disease Rating Scale (UPDRS) part III motor score and Mini-Mental State Examination score were used to assess motor and cognition progression. RESULTS: Plasma NfL levels were significantly higher in the MSA group than in the PD and healthy groups (35.8 ± 6.2, 17.6 ± 2.8, and 10.6 ± 2.3 pg/mL, respectively, p < 0.001). In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr stage and patients with dementia (p < 0.001). NfL levels were modestly correlated with UPDRS part III scores (r = 0.42, 95% confidence interval 0.46-0.56, p < 0.001). After a mean follow-up of 3.4 ± 1.2 years, a Cox regression analysis adjusted for age, sex, disease duration, and baseline motor or cognitive status showed that higher baseline NfL levels were associated with higher risks for either motor or cognition progression (p = 0.029 and p = 0.015, respectively). CONCLUSIONS: Plasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that plasma NfL level distinguishes PD from MSA and is a surrogate biomarker for PD progression.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lin CH, Li CH, Yang KC, et al. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology. 2019. PMID: 31420461. doi:10.1212/WNL.0000000000008088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。